Aligos Therapeutics, Inc.
ALGS · Biological Products, (No Diagnostic Substances) · 42.6M shares · -62%/yr ↓ buyback · EDGAR filings ↗
Grade
D44Clinical/early-stage biotech — liver-disease clinical, heavy burn, funded.
Strengths
- Liquidity — current ratio 3.9 (48th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -1106.7%)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC, FMR LLC
- Buying back stockNet buyback — share count -62%/yr over 2y
- Revenue declineRevenue -39.5% YoY
- Notable holderHeld by 2 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-4024.9%
Net margin
-1106.7%
Return on equity
-45.2%
Return on assets
-27.3%
Revenue growth (QoQ)
-39.5%
Current ratio
3.9×
Tangible book value
$54M
Cash & investments
$78M
Stock comp / revenue
230.7%
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-26 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-07 | ResultsExhibits | filing ↗ |
| 2026-04-21 | Material agreement | filing ↗ |
| 2026-04-14 | OtherExhibits | filing ↗ |
| 2026-03-05 | ResultsExhibits | filing ↗ |
| 2026-02-04 | Exec/director change | filing ↗ |
| 2025-11-06 | ResultsExhibits | filing ↗ |
| 2025-08-06 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-26 | 2026-06-25 | 0001193125-26-285426 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001171843-26-003156 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001193125-26-212001 ↗ |
| 8-K | 2026-04-21 | 2026-04-16 | 0001193125-26-166987 ↗ |
| 8-K | 2026-04-14 | 2026-04-14 | 0001193125-26-154927 ↗ |
| 8-K | 2026-03-05 | 2026-03-05 | 0001171843-26-001340 ↗ |
| 10-K | 2026-03-05 | 2025-12-31 | 0001193125-26-092614 ↗ |
| 8-K | 2026-02-04 | 2026-01-29 | 0001193125-26-037558 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001171843-25-007075 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001193125-25-268203 ↗ |
| 10-Q | 2025-08-06 | 2025-06-30 | 0000950170-25-104042 ↗ |
| 8-K | 2025-08-06 | 2025-08-06 | 0001171843-25-005116 ↗ |